Ascendia

  MARKET NEWS

Navin Molecular to Invest Up to $35 Million to Expand GMP Manufacturing Capabilities
Ovid Therapeutics & Graviton Bioscience Announce Topline Data From Phase 1 Clinical Trial Studying a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
Biora Therapeutics Announces Completion of Multiple-Ascending Dose Cohorts for Clinical Trial of BT-600
Syncromune Granted FDA Fast-Track Designation for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain
NeOnc Technologies Completes $18.5-Million Financing, Advances Phase 2 Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
Nxera Pharma Receives $10 Million From AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
GRI Bio Announces Patent Granted for Proprietary Natural Killer T Cell Modulators
Inmagene Announces Positive Topline Results of a Multiple Ascending Dose Study of  a Non-Covalent Reversible BTK Inhibitor With Once- Daily Dosing Potential

  EXPERT CONTENT & RESOURCES

How AbbVie Operations & Contract Manufacturing Has Prepared Global Parenteral Sites for the Annex 1 Compliance Requirement

How AbbVie Operations & Contract Manufacturing Has Prepared Global Parenteral Sites for the Annex 1 Compliance Requirement

This article explains the key changes that pharmaceutical companies and CMOs engaged in manufacturing and fill-finish need to consider, as well as what AbbVie Contract Manufacturing (AbbVie CMO) is doing to ensure its global operations and aseptic fill-finish sites are in compliance with the revised regulations….

3 Key Things to Consider When Choosing a Partner for Your Tech Transfer

3 Key Things to Consider When Choosing a Partner for Your Tech Transfer

One way of streamlining tech transfer is to partner with a CMO demonstrating a proven track record across the entire drug development and manufacturing continuum. Not only will an experienced CMO partner have the scientific….

Lyophilization Trends in Pharma & Biopharma Drug Development

Lyophilization Trends in Pharma & Biopharma Drug Development

This 30-page eBook is exactly what you have been looking for. Find out what is driving the lyophilization market and how working with a CDMO will save time and money and help you comply with increasing regulatory requirements.

Premium Cell Culture Ingredients From Actylis

Premium Cell Culture Ingredients From Actylis

Thanks to our many GMP manufacturing sites located in North America, Europe and Asia we can provide the critical ingredients for your Biopharma manufacturing applications.

  FEATURED EDITORIAL

  COMPANY PROFILE

Phosphorex, a leading CDMO located just 26.2 miles from Boston in Hopkinton, MA. Our state-of-the-art facility spans at 30,000 Sq. Ft., with an additional 12,000 Sq. Ft. of cGMP space set to come online in 2024. With our expertise and innovative technologies, we excel in encapsulating drugs into microspheres or nanoparticles, enabling targeted delivery, protection of therapeutic agents, controlled release, and improved bioavailability. From proof-of-concept to clinical studies, our integrated solution supports all phases of formulation development. Click here for more.

  WHITEPAPERS & WEBINARS

WEBINAR - Development of Orally Delivered GLP-1 Therapeutics…From Diabetes to Obesity and Beyond

WEBINAR - Development of Orally Delivered GLP-1 Therapeutics…From Diabetes to Obesity and Beyond

Join Quotient Sciences’ experts on July 18 as we explore the latest developments in orally-delivered GLP-1 agonists, the potential for these therapeutics and overcoming the manufacturing challenges.

  WHITEPAPERS & WEBINARS

WHITEPAPER: Optimizing Oral Drug Delivery Using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges

WHITEPAPER: Optimizing Oral Drug Delivery Using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges

Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered mental status and physical impairments find swallowing tablets to be difficult. Orally disintegrating tablets (ODTs), which dissolve completely without chewing …

WHITEPAPER - A Holistic Approach to Getting the First Batch Right

WHITEPAPER - A Holistic Approach to Getting the First Batch Right

By: Mark Rauckhorst, Director Supply Chain and Project Management, Vetter Development Service USA. Inc.

Clinical trials are high-visibility milestones for investors, as this is often the first major step toward financial return on what has likely been years of investment …

WHITEPAPER - Efficient Development of Miniature Drug-Loaded Implants

WHITEPAPER - Efficient Development of Miniature Drug-Loaded Implants

Drug-eluting implants offer a unique approach to overcoming challenges associated with traditional drug delivery methods. They can provide sustained, continuous release of a therapeutic at the desired site of action.

Download our latest white paper, jointly authored with MeltPrep, to …

WHITE PAPER: HPAPI Drug Solid Oral Dosage (SOD) Manufacturing – Ensuring Content Uniformity

WHITE PAPER: HPAPI Drug Solid Oral Dosage (SOD) Manufacturing – Ensuring Content Uniformity

What techniques should manufacturers employ when working with low-dose drug products?

By: Thomas Daggs, MBA, Vice President, Product Development & Quality Control, and Angelo Consalvo, Director of Manufacturing, Enteris BioPharma

Anyone who takes an oral tablet medication – whether prescribed …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 10 – Analytical Testing
August 7 – Injection Devices